IRSF proudly invest in research at every stage: from basic science that can change the way we think about MeCP2 to clinical research that directly impacts potential treatments. We also help connect Rett researchers with external funding opportunities.
2024 Rett Syndrome Innovation Awards
The Rett Syndrome Innovation Awards seek to advance research aimed at investigating the underlying pathology of the disorder and identifying novel therapeutic approaches to treat and cure Rett syndrome. The program aims to (1) provide seed money for innovative research that leads to the identification of therapeutic targets or approaches to treat Rett syndrome, (2) assist investigators to establish careers in the field of Rett syndrome research, and (3) lead to follow-on funding from other agencies. IRSF is grateful to all our donors whose generous support drives our research funding program.
Funding Level:
Up to $300,000 total for two years (up to $150,000 per year)
Timeline:
Letter of Intent – Due May 15, 2024
Full Proposal (by invitation) – Due July 7, 2024
Although we have identified the following areas of interest, the list is not meant to be exclusive.
• Molecular, cellular and circuit level characterization of MeCP2 function to generate novel therapeutic targets/approaches
• Integrated multi-level characterization of Rett Syndrome disease states including pre- and post-regression phases in disease models encompassing both the loss of and the restoration of MeCP2 function
• Identify and engage modulators of MeCP2 function for the development of novel therapeutic targets
• US and non-US independent investigators with an appointment at an academic, government, non-profit research institution or biotechnology/pharmaceutical company
• History of independent publication record
• History of grant support in which the applicant is the principal investigator (PI)
Scientists from underrepresented groups are encouraged to apply.